Vanita R Aroda

List of Publications by Year
in descending order

82 papers	5,547 citations	147801 31 h-index	85541 71 g-index
84 all docs	84 docs citations	84 times ranked	4947 citing authors

#	Article	IF	Citations
1	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished Î²-Cell Function in Patients With Type 2 Diabetes in the GRADE Study. Diabetes, 2022, 71, 1261-1271.	0.6	11
2	Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE). Diabetes Research and Clinical Practice, 2022, 184, 109188.	2.8	4
3	9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesâ€"2022. Diabetes Care, 2022, 45, S125-S143.	8.6	534
4	Use of Lipid-, Blood Pressureâ€“, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA Network Open, 2022, 5, e2148030.	5.9	30
5	Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes. Diabetes Care, 2022, 45, 766-768.	8.6	8
6	Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the <scp>PIONEER</scp> phase 3 programme. Diabetes, Obesity and Metabolism, 2022, 24, 1338-1350.	4.4	12
7	6. Glycemic Targets: Standards of Medical Care in Diabetesâ€"2022. Diabetes Care, 2022, 45, S83-S96.	8.6	388
8	SURPASSing the current dogma: is our framework shifting?. Lancet Diabetes and Endocrinology,the, 2022, , .	11.4	0
9	Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort. Diabetes Care, 2022, 45, 1512-1521.	8.6	0
10	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 979-994.	5.7	13
11	Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080.	4.4	16
12	Gastrointestinal adverse events with insulin glargine/lixisenatide fixedâ€ratio combination versus glucagonâ€like peptideâ€1 receptor agonist<scp>s</scp> in people with type 2 diabetes mellitus: A network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 136-146.	4.4	12
13	Glycaemic control and hypoglycaemia risk with insulin glargine 300â€‰U/mL and insulin degludec 100â€‰U/mL in older participants in the BRIGHT trial. Diabetes, Obesity and Metabolism, 2021, 23, 1588-1593.	4.4	7
14	Switching to <scp>iGlarLixi</scp> versus continuation of a daily or weekly glucagonâ€like peptideâ€1 receptor agonist (<scp>GLP</scp>â€1 <scp>RA</scp>) in insufficiently controlled type 2 diabetes: A <scp>LixiLanâ€G</scp> trial subgroup analysis by HbA1c and <scp>GLP</scp>â€1 <scp>RA</scp> use at screening. Diabetes, Obesity and Metabolism, 2021, 23, 1331-1341.	4.4	2
15	Insights into the early use of oral semaglutide in routine clinical practice: The <scp>IGNITE</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 2177-2182.	4.4	25
16	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	1.6	34
17	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2021, 44, 2286-2292.	8.6	4
18	Effect of insulin degludec versus insulin glargine <scp>U100</scp> on time in range: <scp>SWITCH PRO</scp>, a crossover study of basal insulinâ€treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes, Obesity and Metabolism, 2021, 23, 2572-2581.	4.4	14

#	Article	IF	Citations
19	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. Current Diabetes Reports, 2021, 21, 41.	4.2	15
20	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes Care, 2021, 44, 774-780.	8.6	6
21	Diabetes With Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1599-1602.	2.8	6
22	Impact of baseline characteristics and betaâ€cell function on the efficacy and safety of subcutaneous onceâ€weekly semaglutide: A patientâ€level, pooled analysis of the SUSTAIN 1â€5 trials. Diabetes, Obesity and Metabolism, 2020, 22, 303-314.	4.4	19
23	A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100â€‰units/mL at 26â€‰weeks: DUAL VIII, a randomized trial designed to resemble clinical practice. Diabetes, Obesity and Metabolism, 2020, 22, 873-878.	4.4	6
24	REWIND to fast forward: time to revisit stroke prevention in type 2 diabetes?. Lancet Diabetes and Endocrinology,the, 2020, 8, 90-92.	11.4	5
25	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open, 2020, 10, e037883.	1.9	6
26	EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction. Lancet Diabetes and Endocrinology,the, 2020, 8, 932-933.	11.4	1
27	Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate Medicine, 2020, 132, 26-36.	2.0	12
28	Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program. BMJ Open Diabetes Research and Care, 2020, 8, e001841.	2.8	5
29	<scp>iGlarLixi</scp> effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the <scp>LixiLanâ€L</scp> study. Diabetes, Obesity and Metabolism, 2020, 22, 1683-1689.	4.4	11
30	Adults with early-onset type 2 diabetes (aged 18â€“39Âyears) are severely underrepresented in diabetes clinical research trials. Diabetologia, 2020, 63, 1516-1520.	6.3	15
31	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. JAMA Cardiology, 2020, 5, 1182.	6.1	59
32	Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L. Diabetes Therapy, 2020, 11, 1007-1015.	2.5	5
33	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care, 2020, 43, 940-947.	8.6	14
34	Efficacy and safety of <scp>iGlarLixi</scp> versus <scp>IDegLira</scp> in adults with type 2 diabetes inadequately controlled by glucagonâ€like peptideâ€1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes, Obesity and Metabolism, 2020, 22, 2170-2178.	4.4	11
35	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e130-e138.	3.6	22
36	Reproducibility of a prediabetes classification in a contemporary population. Metabolism Open, 2020, 6, 100031.	2.9	6

#	Article	IF	Citations
37	ApolipoproteinÂJ is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. Nature Communications, 2020, 11, 2024.	12.8	34
38	Impact of disease duration and Î²â€cell reserve on the efficacy of switching to <scp>iGlarLixi</scp> in adults with type 2 diabetes on glucagonâ€like peptideâ€1 receptor agonist therapy: Exploratory analyses from the <scp>LixiLanâ€G</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1567-1576.	4.4	9
39	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Advances in Therapy, 2019, 36, 2310-2326.	2.9	2
40	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2019, 42, 2098-2107.	8.6	37
41	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care, 2019, 42, 2108-2116.	8.6	50
42	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019, 42, 2262-2271.	8.6	146
43	Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 520-530.	27.0	423
44	Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. Diabetes, Obesity and Metabolism, 2019, 21, 2203-2210.	4.4	55
45	Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 596-605.	11.4	46
46	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 1724-1732.	8.6	227
47	Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care, 2019, 42, 601-608.	8.6	82
48	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. Current Diabetes Reports, 2019, 19, 157.	4.2	7
49	Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. Clinical Diabetes, 2018, 36, 138-147.	2.2	10
50	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 275-286.	11.4	443
51	A review of GLPâ€1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 22-33.	4.4	183
52	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 2018, 41, 258-266.	8.6	350
53	Metformin and Type 2 Diabetes Prevention. Diabetes Spectrum, 2018, 31, 336-342.	1.0	26
54	Development of clinical trials to extend healthy lifespan. Cardiovascular Endocrinology and Metabolism, 2018, 7, 80-83.	1.1	59

#	Article	IF	Citations
55	Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L. Diabetes Therapy, 2018, 9, 2155-2162.	2.5	6
56	A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. GeroScience, 2018, 40, 419-436.	4.6	221
57	Response to Letter to the Editor: â€œAndrogens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Programâ€. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2068-2068.	3.6	0
58	More patients reach glycaemic control with a fixedâ€ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc timeâ€toâ€control analysis of LixiLanâ€O and LixiLanâ€L. Diabetes, Obesity and Metabolism, 2018, 20, 2314-2318.	4.4	14
59	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care, 2018, 41, 1590-1599.	8.6	16
60	Efficacy of iGlarLixi, a fixedâ€ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements. Diabetes, Obesity and Metabolism, 2018, 20, 2680-2684.	4.4	4
61	Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlarâ€”A Subanalysis of LixiLan-L. Diabetes, 2018, 67, 1094-P.	0.6	1
62	Upper and/or lower gastrointestinal adverse events with glucagonâ€like peptideâ€1 receptor agonists: <scp>I</scp>ncidence and consequences. Diabetes, Obesity and Metabolism, 2017, 19, 672-681.	4.4	53
63	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current Cardiology Reports, 2017, 19, 25.	2.9	2
64	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 355-366.	11.4	288
65	Consistent findings in glycaemic control, body weight and hypoglycaemia with <scp>iGlarLixi</scp> (insulin glargine/lixisenatide titratable fixedâ€ratio combination) vs insulin glargine across baseline <scp>HbA1c</scp>, <scp>BMI</scp> and diabetes duration categories in the <scp>LixiLanâ€L</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 1408-1415.	4.4	23
66	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes, Obesity and Metabolism, 2017, 19, 1529-1536.	4.4	52
67	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. Current Diabetes Reports, 2016, 16, 44.	4.2	19
68	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care, 2016, 39, 1972-1980.	8.6	198
69	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Diabetes Care, 2016, 39, 1579-1586.	8.6	72
70	Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1754-1761.	3.6	336
71	Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Review of Endocrinology and Metabolism, 2015, 10, 381-398.	2.4	0
72	Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment. Metabolism: Clinical and Experimental, 2013, 62, 1587-1596.	3.4	36

#	Article	IF	Citations
73	Cross-Sectional Evaluation of Noninvasively Detected Skin Intrinsic Fluorescence and Mean Hemoglobin A1c in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 117-123.	4.4	21
74	U.S. Preventive Services Task Force Criteria for Diabetes Screening. American Journal of Preventive Medicine, 2013, 45, 246-247.	3.0	2
75	Scientific Statement: Socioecological Determinants of Prediabetes and Type 2 Diabetes. Diabetes Care, 2013, 36, 2430-2439.	8.6	130
76	Skin Intrinsic Fluorescence Is Associated With Coronary Artery Disease in Individuals With Long Duration of Type 1 Diabetes. Diabetes Care, 2012, 35, 2331-2336.	8.6	34
77	Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics, 2012, 34, 1247-1258.e22.	2.5	229
78	The safety and tolerability of GLPâ€1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews, 2011, 27, 528-542.	4.0	86
79	Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes. Postgraduate Medicine, 2011, 123, 228-238.	2.0	25
80	Skin Intrinsic Fluorescence Correlates With Autonomic and Distal Symmetrical Polyneuropathy in Individuals With Type 1 Diabetes. Diabetes Care, 2011, 34, 1000-1005.	8.6	35
81	Metabolic and Hormonal Changes Induced by Pioglitazone in Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 469-476.	3.6	62
82	Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertility and Sterility, 2008, 89, 1200-1208.	1.0	55